美国成人COVID-19疫苗加强剂接种安全性监测(2021年9月22日至2022年2月6日)
CDC审查了v-safe和VAERS报告的不良事件,发现同源mRNA加强剂后全身反应(58.4%辉瑞、64.4%莫德纳)低于第2剂后(66.7%和78.4%),VAERS收到39286份mRNA加强剂后不良事件报告,其中92.4%为非严重事件。
要点
- 同源mRNA加强剂后全身反应发生率低于第2剂后。
- VAERS收到39286份mRNA加强剂后成人不良事件报告,92.4%为非严重事件。
- 无论基础免疫接种何疫苗,莫德纳加强剂后报告全身反应的调整比值比均更高。
核心结论
- 同源COVID-19 mRNA疫苗加强剂后局部和全身反应常见,但似乎比mRNA疫苗第2剂后更少见。
- CDC和FDA将继续监测疫苗安全性并提供数据以指导疫苗推荐和保护公众健康。
研究设计与样本
- CDC审查了2021年9月22日至2022年2月6日期间向v-safe(自愿性 smartphone 不良事件安全监测系统)和VAERS(CDC与FDA管理的被动疫苗安全监测系统)报告的加强剂后不良事件和健康影响评估。
- v-safe分析纳入721562名≥18岁报告接种加强剂的登记参与者,其中88.8%接种了同源COVID-19 mRNA疫苗。
- VAERS分析纳入≥18岁成人mRNA加强剂后39286份不良事件报告。
主要发现
- 在报告同源COVID-19 mRNA加强剂的登记参与者中,全身反应发生率在加强剂后为58.4%(辉瑞-BioNTech)和64.4%(莫德纳),分别低于第2剂后的66.7%和78.4%。
- 无论基础免疫接种何种疫苗,莫德纳COVID-19疫苗加强剂后报告全身反应的调整比值比均更高。
- VAERS收到的39286份mRNA加强剂后成人不良事件报告中,36282份(92.4%)为非严重事件,3004份(7.6%)为严重事件。
临床怎么用
- 疫苗接种提供者应告知患者,同源COVID-19 mRNA疫苗加强剂后出现局部和全身反应是预期现象,但这些反应似乎比mRNA疫苗第2剂后更少见。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During September 22, 2021-February 6, 2022, approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.* The Food and Drug Administration (FDA) has authorized a booster dose of either the same product administered for the primary series (homologous) or a booster dose that differs from the product administered for the primary series (heterologous). These booster authorizations apply to all three COVID-19 vaccines used in the United States (1-3).† The Advisory Committee on Immunization Practices (ACIP) recommended preferential use of an mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer-BioNTech]) for a booster, even for persons who received the Ad26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine for their single-dose primary series.§ To characterize the safety of COVID-19 vaccine boosters among persons aged ≥18 years during September 22, 2021-February 6, 2022, CDC reviewed adverse events and health impact assessments following receipt of a booster that were reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA. Among 721,562 v-safe registrants aged ≥18 years who reported receiving a booster, 88.8% received homologous COVID-19 mRNA vaccination. Among registrants who reported a homologous COVID-19 mRNA booster dose, systemic reactions were less frequent following the booster (58.4% [Pfizer-BioNTech] and 64.4% [Moderna], respectively) than were those following dose 2 (66.7% and 78.4%, respectively). The adjusted odds of reporting a systemic reaction were higher following a Moderna COVID-19 vaccine booster, irrespective of the vaccine received for the primary series. VAERS has received 39,286 reports of adverse events after a COVID-19 mRNA booster vaccination for adults aged ≥18 years, including 36,282 (92.4%) nonserious and 3,004 (7.6%) serious events. Vaccination providers should educate patients that local and systemic reactions are expected following a homologous COVID-19 mRNA vaccine booster; however, these reactions appear less common than those following dose 2 of an mRNA-based vaccine. CDC and FDA will continue to monitor vaccine safety and provide data to guide vaccine recommendations and protect public health.
引用
- Hause AM, Baggs J, Marquez P, et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35176008. doi:10.15585/mmwr.mm7107e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。